Kelli Whitlock Burton is a reporter at MDEdge and Medscape. She covers a range of topics within health and wellness, focusing on medicine and healthcare, including the FDA, drug trafficking, and cannabis. Kelli's work has been featured in prominent outlets such as MDEdge and Medscape.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kelli Whitlock Burton's coverage predominantly revolves around healthcare, pharmaceuticals and scientific research. Her articles are data-driven, focusing on various health conditions including traumatic brain injury, cognitive function, dementia, ultrasprocessed foods and more. If you are a researcher or professional with access to new data or insights related to these topics, providing relevant statistics and evidence-based information could be compelling for her coverage.
Given the extensive use of data in Kelli's articles, she may respond well to pitches that include recent studies or statistical analysis supporting healthcare-related claims. Providing unique datasets or access to experts who can interpret complex medical findings would likely interest her.
Although there is no specific geographic focus mentioned for Kelli's work, it seems that she covers global health issues without specific regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under
The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under
Having two copies of the APOE4 gene may be the genetic cause of up to one fifth of all Alzheimer's disease (AD) cases, a new study suggests.
Two copies of APOE4 may be more than just a risk factor for AD; the pair may cause the disease in 15%-20% of cases.
By: Kelli Whitlock Burton
Having two copies of the APOE4 gene may be the genetic cause of up to one fifth of all Alzheimer’s disease cases, a new study suggests.
The DOJ issued a notice of proposed rulemaking on Thursday, jumpstarting a 60-day public comment period on rescheduling marijuana from Schedule I to Schedule III.
Zurnai, from Purdue, is the first nalmefene hydrochloride auto-injector for known or suspected opioid overdose in people aged 12 years and older.
By: Alicia Ault, Kelli Whitlock Burton
The US Food and Drug Administration (FDA) has declined to approve a treatment that combines the psychedelic drug midomafetamine with assisted therapy (MDMA-AT) for the treatment of posttraumatic stress disorder (PTSD).
A report published earlier this year by the US Senate Special Committee on Aging is calling for a national coordinated response to what the authors claim may be an emerging hoarding disorder (HD) crisis.
Whether a restrictive or liberal transfusion strategy offers the best outcomes after acute brain injury has been the subject of ongoing debate. Will publication of a new study end it?
(833) 317-6278 
